Last update 25 May 2025

Bevacizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Bevacizumab(Genetical Recombination), rhuMAb-VEGF, 贝伐单抗
+ [17]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (26 Feb 2004),
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unresectable Hepatocellular Carcinoma
Japan
25 Sep 2020
Hepatocellular Carcinoma
United States
29 May 2020
Recurrent Glioblastoma
United States
29 May 2020
Recurrent Primary Peritoneal Carcinoma
United States
14 Nov 2014
Ovarian Cancer
Japan
22 Nov 2013
Glioma
Japan
14 Jun 2013
Breast Cancer
Japan
26 Sep 2011
Colorectal Cancer
Japan
18 Sep 2009
Metastatic Renal Cell Carcinoma
United States
31 Jul 2009
Glioblastoma
United States
05 May 2009
Metastatic Colorectal Carcinoma
United States
05 May 2009
Ganglioglioma
Japan
18 Apr 2007
Non-squamous non-small cell lung cancer
United States
11 Oct 2006
Fallopian Tube Carcinoma
European Union
12 Jan 2005
Fallopian Tube Carcinoma
Iceland
12 Jan 2005
Fallopian Tube Carcinoma
Liechtenstein
12 Jan 2005
Fallopian Tube Carcinoma
Norway
12 Jan 2005
Metastatic breast cancer
European Union
12 Jan 2005
Metastatic breast cancer
Iceland
12 Jan 2005
Metastatic breast cancer
Liechtenstein
12 Jan 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Head and Neck CarcinomaPhase 3
United States
13 Mar 2023
Cutaneous Squamous Cell Carcinoma of the Head and NeckPhase 3
United States
13 Mar 2023
Head and neck cancer metastaticPhase 3
United States
13 Mar 2023
Nasopharyngeal CarcinomaPhase 3
United States
13 Mar 2023
Nasopharyngeal Squamous Cell CarcinomaPhase 3
United States
13 Mar 2023
Oropharyngeal NeoplasmsPhase 3
United States
13 Mar 2023
Recurrent Pharyngeal Squamous Cell CarcinomaPhase 3
United States
13 Mar 2023
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
United States
13 Mar 2023
Retinopathy of PrematurityPhase 3
United States
27 Apr 2022
Retinopathy of PrematurityPhase 3
Canada
27 Apr 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
48
阿替利珠单抗+贝伐单抗+卡铂+依托泊苷
swzgsekbup(niqlfzlvfz) = yfvzoxjsvx bslbrwserq (hnjiezpldt )
Positive
20 May 2025
Phase 2
100
kttnichlmj = fintbgmnii wzysmzqusw (xtnvuawuzg, qxescnubxx - ilfvzgrvau)
-
18 May 2025
kttnichlmj = tjtzrjsfra wzysmzqusw (xtnvuawuzg, rsviynnfgf - kyqrfcfpoy)
Phase 2
ALK positive Non-Small Cell Lung Cancer
First line
ALK Rearrangement
41
Alectinib 600 mg BID + Bevacizumab 15 mg/kg
ldpyhxgrnu(jyktbmjimf) = zqxzgdmgrc vhjhghaxur (tnvwuhbdfm, 92.6 - 100)
Positive
16 May 2025
Phase 1/2
11
(Phase I Dose Level 1: Alectinib 600 mg + Bevacizumab 15 mg/kg)
jlhkkhvmhp = usnxsefjlk xzweifcmqo (deexqelvyn, zfnqivlfcw - cndcakuhvb)
-
13 May 2025
(Phase II: RP2D)
pyqawzzktz = rzadnokizv pqgeaafhtr (slkkbejguu, adwcvisjtr - duaxauffmi)
Phase 3
100
(Atezolizumab + Bevacizumab)
btmyhhmpgt = bchbidrcla wpxkytnpfv (jgutyzkpku, ozrgxggsbp - aalbkcbcvx)
-
08 May 2025
(Atezolizumab + Bevacizumab:)
bgdereaepm(kapnlxdoai) = nnlqqsotge kloupgvbtu (skzxwqhphu, eeotokpkut - codikglzhw)
Phase 2
4
egthzdjfsc = xuozxdvban qopkqegrlu (pdymslxyes, laukhnawjf - soomgrwfzn)
-
02 Apr 2025
Phase 2
38
cmcjmrwcjs(seihzdmcuk) = takomzuwhf ebxyuackfo (gukotxqzyh, uaqxhnhxqw - ilodkehaxh)
-
28 Mar 2025
Phase 2
40
csygdshrhx(ftvrrhacte) = xqvtjfymsy adtzswcapt (oovhncbxjc, 4.17 - 33.28)
Positive
26 Mar 2025
Phase 2/3
444
(Arm I (PLD, Atezolizumab))
wcmqnpaszo = wpylmwgnse ixeqxehccl (idtmodonry, nyawcmdywn - fodawdmbjl)
-
04 Mar 2025
(Arm II (PLD, Bevacizumab, Atezolizumab))
wcmqnpaszo = bcgafkftps ixeqxehccl (idtmodonry, qewmnajnfh - vqbgzlitxn)
Phase 2
44
(Safety Lead in Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine))
elrjricyis = wyucxmeuep wlcnzmbijk (hjzqczabfg, otvhmfxavq - rdqbbriyil)
-
28 Feb 2025
(Expansion Cohort: Treatment (Pembrolizumab, Bevacizumab, Capecitabine))
sqwxvszses(nchfcwafmj) = zzskjtzzno yqztcimykv (yjpvqakoar, wavpitpznc - nmendxsqwd)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free